Zhejiang Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.zchospital.com

Clinical Trials

A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma

Phase 3

Conditions: Esophageal Cancer

Interventions: Radiation: Adjuvant radiotherapy
Drug: Paclitaxel and carboplatin

First Posted Date: 2015-10-07

Last Posted Date: 2015-10-07

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 366

Registration Number: NCT02570893

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

HIPEC, Intravenous Chemotherapy and Surgery for the Treatment of Advanced GC With Peritoneal Metastasis

Phase 2

Conditions: Gastric Cancer

Interventions: Other: HIPEC,Chemotherapy AND surgery

First Posted Date: 2015-09-15

Last Posted Date: 2015-09-15

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT02549911

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Comparison of Lobectomy and Segmentectomy for cT1aN0M0 Peripheral NSCLC

Phase 3

Conditions: Non-small Cell Lung Cancer

Interventions: Procedure: segmentectomy

First Posted Date: 2015-06-25

Last Posted Date: 2015-06-25

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 610

Registration Number: NCT02481661

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases

Phase 1

Conditions: NSCLC

Interventions: Drug: Temozolomide

First Posted Date: 2015-03-11

Last Posted Date: 2015-03-11

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 135

Registration Number: NCT02385136

Comparable Study of Different Radiation Dose in Esophageal Carcinoma

Phase 3

Conditions: Esophageal Carcinoma

Interventions: Radiation: intensity modulated radiation therapy in both arms
Drug: concurrent chemotherapy with radiation

First Posted Date: 2013-09-09

Last Posted Date: 2013-09-09

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 300

Registration Number: NCT01937208

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection

Phase 2

Conditions: Non-small Cell Lung Cancer Stage IIIA

Interventions: Other: Neoadjuvant Chemoradiotherapy

First Posted Date: 2013-08-21

Last Posted Date: 2013-08-21

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 75

Registration Number: NCT01926483

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma

Phase 3

Conditions: Stage IVC Nasopharyngeal Carcinoma
Effects of Chemotherapy

Interventions: Drug: Gemcitabine and cisplatin
Drug: Recombinant Human Endostatin plus gemcitabine and cisplatin

First Posted Date: 2013-08-02

Last Posted Date: 2015-01-01

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 362

Registration Number: NCT01915134

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer

Phase 2

Conditions: Locally Advanced Rectal Cancer

Interventions: Radiation: Preoperative irradiation
Drug: Nimotuzumab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2013-07-15

Last Posted Date: 2013-07-15

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT01899118

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer

Phase 2

Conditions: Gastric Cancer

Interventions: Procedure: surgery

First Posted Date: 2013-04-22

Last Posted Date: 2013-04-23

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT01836991

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou,, Zhejiang, China

Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Endostar
Drug: Oxaliplatin
Drug: Folinic acid
Drug: 5-FU

First Posted Date: 2013-04-16

Last Posted Date: 2013-04-16

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT01832948

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy